Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales

Executive Summary

Regeneron and Sanofi have opportunity to appeal or to reach resolution with Amgen after district judge delays imposition of permanent injunction for 30 days in PCSK9 patent case.

You may also be interested in...



PCSK9 Patent Battle: Amgen Seeks Supreme Court Review Ahead Of February Trial

Amgen opposes US Federal Circuit's standard for determining adequacy of an invention's written description, which led court to overturn jury verdict that its Repatha patents are valid.

Hemlibra Patent Dispute Spills Over Into Patient Community

After Shire seeks preliminary injunction to carve-out certain patients from obtaining the hemophilia treatment, Genentech issues open letter saying patients should not be put in the middle of a patent dispute.

PCSK9 Patent Case: Praluent Injunction Vacated, But May Well Return

Appeals court vacates injunction that Repatha marketer Amgen had won against Sanofi/Regeneron's Praluent, but notes 'a reduction in choice of drugs cannot be the sole reason for a district court to deny an injunction.'

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel